Emily Pineda, MD
Rheumatology · San Antonio, TXNPI 1376512368
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 922 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations.
Across 922 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Johnson & Johnson$2K
- AbbVie$2K
- Novartis$2K
- UCB, Inc.$1K
- Mallinckrodt Hospital Products Inc.$1K
- plus $6K from 26 others
Across 8 payments — averaging $2744.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$8K
- Janssen Research & Development, LLC$8K
- Amgen$5K
What the payments were for
- Food & beverage$18,56298%
- Education$3972%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 214 | $4,312 |
| Johnson & Johnson(2 entities) | 128 | $2,417 |
| AbbVie | 94 | $1,813 |
| Novartis | 71 | $1,658 |
| UCB, Inc. | 56 | $1,319 |
| Mallinckrodt Hospital Products Inc. | 47 | $1,275 |
| E.r. Squibb & Sons, L.L.C. | 52 | $944 |
| AstraZeneca | 37 | $800 |
| Sanofi | 29 | $777 |
| Lilly USA, LLC | 41 | $744 |
| GSK | 30 | $561 |
| Genentech USA, Inc. | 26 | $451 |
| Radius Health, Inc. | 16 | $378 |
| Antares Pharma, Inc. | 20 | $335 |
| Pfizer | 14 | $219 |
| ANI Pharmaceuticals, Inc. | 8 | $170 |
| Mallinckrodt Enterprises LLC | 5 | $121 |
| Janssen Scientific Affairs, LLC | 3 | $107 |
| Octapharma USA, Inc. | 4 | $85 |
| Hikma Pharmaceuticals USA | 5 | $73 |
| Sobi, Inc | 3 | $68 |
| Aurinia Pharma U.S., Inc. | 2 | $54 |
| Boehringer Ingelheim | 3 | $49 |
| Ultragenyx Pharmaceutical Inc. | 2 | $43 |
| Cumberland Pharmaceuticals, Inc. | 3 | $40 |
| IBSA Pharma Inc. | 3 | $35 |
| Tersera Therapeutics LLC | 1 | $30 |
| Pacira Therapeutics, Inc. | 1 | $25 |
| Zimmer Biomet | 1 | $17 |
| Bristol Myers Squibb | 1 | $16 |
| Medexus Pharma, Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$275
- ACTHAR$131
- SIMPONI ARIA$125
- KEVZARA$121
How this compares
$18,960 in reported general payments places this provider in the 80th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 64 | $629,867 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 11 | $407,224 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $330,303 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 14 | $296,965 |
| RinvoqUpadacitinib | 29 | $224,714 |
| Xeljanz XrTofacitinib Citrate | 28 | $178,270 |
| Cimzia (2 Pack)Certolizumab Pegol | 16 | $169,608 |
| Enbrel MiniEtanercept | 20 | $160,502 |
| BenlystaBelimumab | 26 | $128,270 |
| Orencia ClickjectAbatacept | 14 | $112,714 |
| Cosentyx (2 Syringes)Secukinumab | 14 | $106,393 |
| SaphneloAnifrolumab-Fnia | 12 | $61,023 |
| ProgesteroneProgesterone, Micronized | 333 | $32,476 |
| Hydroxychloroquine Sulfate | 660 | $20,140 |
| Mycophenolate Mofetil | 82 | $12,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Panzyga | $219 | $704,18925 claims |
| AbbVieRinvoq, Armour Thyroid, Synthroid | $1,813 | $231,806115 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,319 | $169,60816 claims |
| GSKBenlysta | $561 | $128,27026 claims |
| NovartisCosentyx (2 Syringes) | $1,658 | $106,39314 claims |
| AstraZenecaSaphnelo | $800 | $61,02312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 512 rheumatology providers in Texas.
Other rheumatology in San Antonio
- Pendleton WickershamSan Antonio$954K
- Thomas RennieSan Antonio$113K
- Kevin KempfSan Antonio$83K
- Alex DejesusSan Antonio$68K
- Jane AyalaSan Antonio$67K
- Pankhuri GuptaSan Antonio$58K
- Fernando SilvaSan Antonio$54K
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.